Adcendo Raises $135M to Advance ADCs Targeting Cancer with Growing Biotech Interest
Adcendo, a Danish biotech firm, has successfully closed a $135 million Series B funding round led by TCGX, with significant participation from RA Capital Management and Novo Holdings among others. The capital raised will be primarily used to propel the development of the company's antibody-drug conjugates (ADCs) targeting cancers with significant unmet clinical needs. The funding supports advancements in Adcendo's leading candidates, such as ADCE-T02, which targets solid tumors, and ADCE-D01, addressing uPARAP receptor-mediated sarcoma treatments[1][2].
References
Explore Further
What are the potential benefits and challenges of using antibody-drug conjugates (ADCs) for treating challenging cancers like colorectal and lung cancer?
How does Adcendo plan to utilize the $135 million funding to advance its ADC programs targeting unmet medical needs in cancer treatment?
What specific technological advancements in Adcendo's ADCs set them apart from existing cancer treatments on the market?
In what ways might Adcendo's ADC candidates, ADCE-T02 and ADCE-D01, impact the current treatment paradigms for solid tumors and sarcoma?
How significant is the expected growth in the ADC market value, from $12 billion to $44 billion by 2029, for biotech companies like Adcendo?